- Pioneering mRNA technology - Moderna
Learn how we’re changing the world of medicine Discover career opportunities, our product pipeline, and browse media resources Meet Moderna
- Our Story - Moderna
Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease–human metapneumovirus (hMPV virus) and parainfluenza virus
- Company Culture - Moderna
Join Moderna as we pursue the uncharted reaches of possibility and make your mark on the future of medicine
- Investor Relations - Moderna
Innovation Incubator New venture labs Terms of Use Site Map Privacy Policy Contact Moderna © 2025 Moderna, Inc
- Modernas mRNA Platform - Moderna
In addition to mRNA vaccines, Moderna is working on other applications of potential mRNA therapeutics that could help people with cancer, metabolic diseases and more
- News and Media – Moderna
Resources for journalists and media members The latest press releases by Moderna
- Spikevax® (COVID-19 Vaccine, mRNA) | Moderna
Learn more about Spikevax® (COVID-19 Vaccine, mRNA) 2025-2026 Formula, Moderna's updated COVID-19 vaccine for individuals aged 12+ For US healthcare providers
- mNEXSPIKE® (COVID-19 Vaccine, mRNA) by Moderna
You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines
|